Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albiglutide Extension Study in T2DM
NCT02750930Phase 4Terminated
- Sponsor
- GSK
- Start
- Oct 2016
- Primary completion
- Mar 2017
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of albiglutide in type 2 diabetes mellitus (T2DM), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With Physical Examination Abnormalities and 7 more. Started Oct 2016; status: terminated.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02750930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02750930.